EGFR Positive Lung Cancer Latest Advances

Find the Latest Research About EGFR Positive Lung Cancer

Last Updated: 09/19/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 7380 publications

Co-Occurring EGFR L858R Mutation and HER2 Amplification in NSCLC Identified by Stepwise Molecular Profiling.

Co-Occurring EGFR L858R Mutation and HER2 Amplification in NSCLC Identified by Stepwise Molecular Profiling.

Journal: The American journal of case reports

Published: September 02, 2026

Holmes tremor as the initial manifestation of EGFR mutated lung cancer

Holmes tremor as the initial manifestation of EGFR mutated lung cancer

Journal: Medicina

Published: August 16, 2026

Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR Variations in Concurrent TP53 Mutations: Research Summary.

Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR Variations in Concurrent TP53 Mutations: Research Summary.

Journal: JAMA

Published: August 10, 2026

Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.

Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.

Journal: JAMA

Published: August 10, 2026

EGFR Wild-Type Sarcomatoid Carcinoma as Acquired Resistance to Tarlatamab in Small Cell-Transformed EGFR-Mutated Lung Adenocarcinoma: A Case Report.

EGFR Wild-Type Sarcomatoid Carcinoma as Acquired Resistance to Tarlatamab in Small Cell-Transformed EGFR-Mutated Lung Adenocarcinoma: A Case Report.

Journal: JTO clinical and research reports

Published: July 28, 2026

Design, synthesis, antitumor estimation, and molecular docking of new imidazothiazolediones as potential dual EGFR and IDO1 inhibitors and apoptosis stimulators.

Design, synthesis, antitumor estimation, and molecular docking of new imidazothiazolediones as potential dual EGFR and IDO1 inhibitors and apoptosis stimulators.

Journal: Bioorganic & medicinal chemistry

Published: July 26, 2026

HDAC6 promotes osimertinib resistance evolution in non-small cell lung cancer by activating EGFR degradation through the ubiquitin-proteasome pathway.

HDAC6 promotes osimertinib resistance evolution in non-small cell lung cancer by activating EGFR degradation through the ubiquitin-proteasome pathway.

Journal: Acta biochimica et biophysica Sinica

Published: July 25, 2026

Race-Associated EGFR and KRAS Mutation Profiles in Lung Adenocarcinoma.

Race-Associated EGFR and KRAS Mutation Profiles in Lung Adenocarcinoma.

Journal: Genes

Published: July 16, 2026

New Treatment Strategies for Rare Genomic Alterations: EGFR Exon 20 Insertions and HER2-Deregulated Lung Cancer.

New Treatment Strategies for Rare Genomic Alterations: EGFR Exon 20 Insertions and HER2-Deregulated Lung Cancer.

Journal: Cancers

Published: July 06, 2026

Novel Co-Occurrence of Germline EGFR p.V843I and Somatic EGFR Exon 19 Deletion in NSCLC: Insights into Reduced Sensitivity to EGFR-TKIs.

Novel Co-Occurrence of Germline EGFR p.V843I and Somatic EGFR Exon 19 Deletion in NSCLC: Insights into Reduced Sensitivity to EGFR-TKIs.

Journal: International journal of molecular sciences

Published: July 05, 2026

Emergence of Microsatellite Instability in an Oncogene-Driven Non-Small Cell Lung Cancer Harboring a Canonical EGFR Mutation: A Molecular Tumor Board Discussion.

Emergence of Microsatellite Instability in an Oncogene-Driven Non-Small Cell Lung Cancer Harboring a Canonical EGFR Mutation: A Molecular Tumor Board Discussion.

Journal: JCO precision oncology

Published: July 01, 2026

Prevalence and Clinical Implications of Somatic and Germline EGFR Mutations in Patients with Non-Small-Cell Lung Cancer.

Prevalence and Clinical Implications of Somatic and Germline EGFR Mutations in Patients with Non-Small-Cell Lung Cancer.

Journal: Cancers

Published: June 30, 2026

Showing 1-12 of 7,380

Last Updated: 09/19/2026